HYPOKALEMIA – EARLY MARKER OF AUTOSOMAL RECESSIVE TUBULOPATHY (GYTELMAN'S SY) - CASE REPORT

  • Milica Petrovic Military Medical Academy
  • Vlastimir Vlatković
  • Dejan Pilćević
  • Violeta
DOI: https://doi.org/10.5937/mckg57-40482
Keywords: Gitelman syndrome, autosomal recessive kidney disease, hypokalemia, metabolic alkalosis.

Abstract


Introduction: Hypokalemia is the most common feature of Gitelman's syndrome, which is a rare, inherited, autosomal recessive kidney disease associated with tubule disease. Apart from hypokalemia, it is most often characterized by hypomagnesemia, metabolic alkalosis, hyperrenemic hyperaldosteronism, normal blood pressure, which can be lower, while the existence of arterial hypertension does not exclude the diagnosis of Gitelman's syndrome. It affects men and women equally, approximately 1-10 cases per 40,000 population. The most common cause are mutations in the SLC12A3 gene that encodes the thiazide-sensitive sodium chloride cotransporter (NCCT) and the TRPM6 (cation channel subfamily 6 protein Claudin 16) gene that controls distal tubular magnesium transport. The aim is to present an adult patient with pronounced hypokalemia as part of Gitelman's syndrome, which is not common in clinical practice. Case report: We present a 21-year-old man with severe hypokalemia as part of Gitelman's syndrome. The disease manifested itself in non-specific complaints, and laboratory findings showed hypokalemia (2.0 mmol/L), which was the reason for urgent hospitalization. Through further examinations, the following were verified in the patient: hypomagnesemia, hypocalciuria, metabolic alkalosis, preserved kidney function and hypotension. Other, potential causes of hypokalemia are excluded by differential diagnosis. He was treated with potassium and magnesium replacement therapy, after which the symptoms disappeared and the electrolyte values improved. The diagnosis of Gitelman's syndrome was made based on clinical and laboratory findings. A geneticist was also consulted.

Conclusion: Hypokalemia as part of Gitelmann's syndrome is rarely encountered in daily clinical practice. It is characterized by a variable clinical picture, with non-specific symptoms, the course and prognosis of which can significantly threaten the patient's life. Timely diagnosis and application of adequate therapy require teamwork and experience of several specialists. Patients with symptoms should be treated symptomatically, and those without symptoms should be monitored 1-2 times a year.

 

Author Biography

Milica Petrovic, Military Medical Academy

Department of nephrology

Nephrologist

References


  1. Blanchard A, Bockenhauer D, Bolignano D, Calò LA, Cosyns E, DevuystO, et al. Gitelman syndrome: consensus and guidance from a kidneydisease: improving global outcomes (KDIGO) controversies conference.Kidney Int. 2017;91:24–33.

  2.  Yang W, Zhao S, Xie Y, Mo Z. A novel SLC12A3 homozygous c2039delG mutation in Gitelman syndrome with hypocalcemia. BMC Nephrol. 2018 Dec 17;19(1):362. [

  3. Hsu YJ, Hoenderop JG, Bindels RJ. TRP channels in kidney disease. Biochim Biophys Acta. 2007 Aug;1772(8):928-36. 

  4.  Mayan H, Farfel Z, Karlish SJD. Renal Mg handling, FXYD2 and the central role of the Na,K-ATPase. Physiol Rep. 2018 Sep;6(17):e13843.

  5. Takeuchi Y, Mishima E, Shima H, Akiyama Y, Suzuki C, Suzuki T, et al . Exonic mutations in the SLC12A3 gene cause exon skipping and premature termination in Gitelman syndrome. J Am Soc Nephrol. 2015 Feb;26(2):271-9. 

  6. Karl P. Schlingmann a and Jeroen H.F. de Baaij .The genetic spectrum of Gitelman(-like) syndromes. Logo of lwwopen.Curr Opin Nephrol Hypertens. 2022 Sep; 31(5): 508–515.

  7. Fukuyama S, Hiramatsu M, Akagi M, Higa M, Ohta T. Novel mutations of the chloride channel Kb gene in two Japanese patients clinically diagnosed as Bartter syndrome with hypocalciuria. J Clin Endocrinol Metab. 2004 Nov;89(11):5847-50. 

  8. Zelikovic I, Szargel R, Hawash A, Labay V, Hatib I, Cohen N, Nakhoul F. A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int. 2003 Jan;63(1):24-32

  9.  Knoers NV, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis. 2008 Jul 30;3:22. 

  10. Pachulski RT, Lopez F, Sharaf R. Gitelman's not-so-benign syndrome. N Engl J Med. 2005 Aug 25;353(8):850-1.

  11. Peters M, Jeck N, Reinalter S, Leonhardt A, Tönshoff B, Klaus G Gü, Konrad M, Seyberth HW. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med. 2002 Feb 15;112(3):183-90. 

  12. Fujimura J, Nozu K, Yamamura T, Minamikawa S, Nakanishi K, Horinouchi T, et a. Clinical and Genetic Characteristics in Patients With Gitelman Syndrome. Kidney Int Rep. 2019 Jan;4(1):119-125. 

  13. Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A. Hypokalemia: a clinical update. Endocr Connect. 2018;7:R135–R146. doi: 10.1530/EC-18-0109.

  14. Khitan ZJ, Shweihat YR, Tzamaloukas AH, Shapiro JI. Dietary potassium and cardiovascular profile. Results from the modification of diet in renal disease dataset. Journal of Clinical Hypertension 2018. 611–612.

  15. Palmer BF, Perazella MA, Choi MJ. American Society of Nephrology Quiz and Questionnaire 2013: electrolyte and acid-base. Clinical Journal of the American Society of Nephrology 2014. 9 1132–1137.

  16. Patel K, McCoy JV, Davis PM. Recognizing thyrotoxic hypokalemic periodic paralysis. JAAPA 2018. 31 31–34.


17.  Efstratios Kardalas, Stavroula A Paschou, Panagiotis Anagnostis, Giovanna Muscogiuri,  Gerasimos Siasos, and Andromachi Vryonidou. Hypokalemia: a clinical update. Endocr Connect. 2018 Apr; 7(4): R135–R146.



  1. Elliott TL Electrolytes: Potassium Disorders. FP Essentials 2017. 459 21–28.


 



  1. Dhondup T, Qian Q. Acid-base and electrolyte disorders in patients with and without chronic kidney disease: an update. Kidney Disease 2017. 3 136–148.


 



  1. Udensi UK, Tchounwou PB. Potassium homeostasis, oxidative stress, and human disease. International Journal of Clinical and Experimental Physiology 2017. 4 111–122.


 



  1. Cortesi C, Lava SA, Bettinelli A, Tammaro F, Giannini O, Caiata-Zufferey M, Bianchetti MG. Cardiac arrhythmias and rhabdomyolysis in Bartter-Gitelman patients. Pediatr Nephrol. 2010 Oct;25(10):2005-8.

  2. Blanchard A, Bockenhauer D, Bolignano D, Calò LA, Cosyns E, Devuyst O et al. Gitelman syndrome: Consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 91: 24–33, 2017

  3. Pachulski RT, Lopez F, Sharaf R. Gitelman's not‐so‐benign syn‐ drome. N Engl J Med. 2005;353:850‐851. 25. Gitelman HJ, Graham JB, Welt LG. A new familial disorder char‐ acterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians. 1966;79:221‐235. 

  4. Thomas CP. Metabolic acidosis. In Medscape Ed V Batuman. New York, NY, USA: WebMD LLC, 2017. (avalable at: https://emedicine.medscape.com/article/242975-overview)


25.  Wang L, Dong C, Xi YG, Su X. Thiazide-sensitive Na+-Cl- cotransporter: genetic polymorphisms and human diseases. Acta Biochim Biophys Sin (Shanghai). 2015 May;47(5):325-34. 


26.  Matsunoshita N, Nozu K, Shono A, Nozu Y, Fu XJ, Morisada N et al. Differential diagnosis of Bartter syndrome, Gitelman syndrome, and pseudo-Bartter/Gitelman syndrome based on clinical characteristics. Genet Med. 2016 Feb;18(2):180-8..



  1. Malvinder S. Parmar; Vijayadershan Muppidi; Khalid Bashir. Gitelman Syndrome. StatPearls [Internet]. Last Update: May 27, 2022.

  2. Peng X, Zhao B, Zhang L, Jiang L, Yuan T, Wang Y,et al. Hydrochlorothiazide Test as a Tool in the Diagnosis of Gitelman Syndrome in Chinese Patients. Front Endocrinol (Lausanne). 2018;9:559. 


29.  Matsunoshita N, Nozu K, Yoshikane M, Kawaguchi A, Fujita N, Morisada N, et al. Congenital chloride diarrhea needs to be distinguished from Bartter and Gitelman syndrome. J Hum Genet. 2018 Jul;63(8):887-892. 

Published
2023/12/13
Issue
Vol. 57 No. 1 (2023): MEDICINSKI ČASOPIS
Section
Review